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Keratinocytes Function as Accessory Cells for
Presentation of Endogenous Antigen Expressed in
the Epidermis
Brian S. Kim1,2, Fumi Miyagawa1, Young-Hun Cho1, Clare L. Bennett3,4, Bjo¨rn E. Clausen3,4 and
Stephen I. Katz1
The precise contribution(s) of skin dendritic cells (DCs) to immune responses in the skin has not been well
delineated. We developed an intradermal (i.d.) injection model in which CD8þ T (OT-I) cells that express
ovalbumin (OVA) peptide-specific TCRs (Va2/Vb5) are delivered directly to the dermis of transgenic (Tg) mice
expressing OVA in the epidermis. After i.d. injection, these mice reliably develop skin graft-versus-host disease
(GVHD) by day 7. To determine the relative contribution of Langerhans cells (LCs) to the ensuing GVHD-like
reaction, we generated K14-OVA Langerin-diphtheria-toxin-receptor (Langerin-DTR) Tg mice to allow
conditional ablation of LCs in the epidermis. To delineate the role of dermal DCs (dDCs) in the reaction, we
also generated K14-OVATg chimeras using b2-microglobulin-deficient (b2m) congenic donor bone marrow cells.
Dermal DCs in these mice cannot present OVA to autoreactive T cells (OT-I cells), whereas the LCs are antigen
presentation-competent. Unexpectedly, OT-I cell injection into diphtheria toxin (DT)-treated b2m-
K14OVA Langerin-DTR Tg mice resulted in skin GVHD. Thus, in vivo, both LC and dDC appear to be
dispensable for the induction of keratinocyte-directed, CD8-mediated effector immune responses. Furthermore
and surprisingly, OVA-expressing epidermal cells depleted of LCs that could not initiate allogeneic epidermal
lymphocyte reactions activated naive OT-I cells in vitro. These results indicate that keratinocytes may function as
accessory cells competent to prime naive skin-reactive T cells.
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INTRODUCTION
Dendritic cells (DCs) are the primary antigen-presenting cells
(APCs) that mediate T-cell immunity and tolerance (Bancher-
eau and Steinman, 1998; Hawiger et al., 2001; Probst et al.,
2003). In skin, it is thought that epidermal Langerhans cells
(LCs) and dermal DCs (dDCs) serve this role by taking up
antigen (Ag) in the periphery and acting as sentinels. In the
immature state, DCs express low levels of surface costimulatory
molecules and induce tolerance on interaction with naive T
cells (Hawiger et al., 2001; Steinman and Nussenzweig, 2002;
Probst et al., 2003). After activation by pathogenic stimuli,
skin DCs upregulate major histocompatibility complex II
(MHC II), CD40, CD80, and CD86 molecules and migrate to
the skin-draining lymph nodes (LNs) to prime naive T cells
(Stoitzner et al., 1999; Hemmi et al., 2001; Carbone et al.,
2004). It has been suggested that LCs continuously migrate to
the cutaneous LN to maintain tolerance to self-Ag; however,
a series of recent studies have suggested that LCs may have
an immunostimulatory function even in the steady state
(Azukizawa et al., 2003; Mayerova et al., 2004; Shibaki et al.,
2004). Thus, the precise role of LCs in the induction of
tolerance and immunity remains unclear. The role of dDCs
has remained even more elusive.
Recent studies suggest several possibilities regarding the
relative contributions of skin DCs (LCs and dDCs) to cross-
presentation of skin-derived Ag, T-cell priming, viral im-
munity, and contact hypersensitivity (CHS). With regard to
CHS, elimination of LCs repeatedly resulted in three out-
comes: no effect, attenuation, and enhancement of CHS
responses (Bennett et al., 2005; Kaplan et al., 2005;
Kissenpfennig et al., 2005). Despite varying results, each of
these studies indicated that dDCs are sufficient to elicit a
significant CHS response. However, the relative contributions
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We previously described a systemic graft-versus-host-
disease (GVHD) model in which mice that expressed a
membrane-bound form of ovalbumin (mOVA) regulated by a
keratin 14 (K14) promoter developed weight loss and skin and
esophageal lesions after intravenous (i.v.) transfer of autoreac-
tive T cells (OT-I cells) (Shibaki et al., 2004). To better
understand the mechanisms underlying Ag presentation within
the skin, we developed an intradermal (i.d.) injection model in
which OT-I cells are delivered directly into the dermis of
different lines of K14-OVA transgenic (Tg) mice and elicit
localized GVHD reactions. To examine the role of LCs in this
reaction, we generated K14-OVA Langerin-diphtheria-toxin-
receptor (Langerin-DTR) double-Tg mice to allow conditional
ablation of LCs after administration of diphtheria toxin (DT)
(Bennett et al., 2005). To determine the contribution of dDCs
(and potential circulating DC precursors), we chimerized K14-
OVA Tg mice with congenic b2-microglobulin-deficient (b2m)
bone marrow cells to impair the presentation of OVA Ag
through MHC class I molecules. Surprisingly, we determined
that the elimination of epidermal LCs and/or the impairment of
dDCs did not abrogate localized GVHD reactions in vivo. We
also show that the elimination of LCs from the epidermis could
abrogate mixed epidermal lymphocyte reactions (MELRs) but
did not attenuate OT-I T-cell priming. These results indicate
that keratinocytes can present self-Ag that is expressed in
epidermis to naive CD8 T cells.
RESULTS
OVA mRNA expression level varies between the different lines
of K14-OVA Tg mice
Five Tg mouse lines that express either soluble (K14-sOVA(5),
K14-sOVA(15), and K14-sOVA(17) Tg) or membrane-bound
(K14-mOVA(3) and K14-mOVA(6) Tg) forms of OVA in
epidermis were established. OVA mRNA expression levels
were quantified by real-time reverse transcription-PCR in ears
(Figure 1) and trunk skin (data not shown). K14-mOVA(6) Tg
mice develop systemic GVHD after i.v. transfer of OT-I cells
manifested by histological signs and 30% weight loss by day 7
(Shibaki et al., 2004). K14-sOVA(15) Tg mice that express the
highest level of OVA mRNA (Figure 1) developed more severe
disease and died by days 4–5 after adoptive transfer of OT-I
cells (data not shown). In contrast to the K14-mOVA(6) and
K14-sOVA(15) Tg mice, other strains (K14-mOVA(3), K14-
sOVA(5), and K14-sOVA(17) Tg) that expressed lower levels
of OVA mRNA did not develop systemic GVHD after i.v.
transfer of OT-I cells (data not shown). Thus, the development
of systemic GVHD reactions after i.v. transfer of OT-I cells
correlates well with the level of OVA mRNA expression.
All lines of K14-OVA Tg mice develop localized GVHD after i.d.
injection of OT-I cells
To additionally investigate the mechanism of GVHD in skin,
2 106 OT-I cells were injected i.d. into the ears of all lines of
K14-OVA Tg mice. After i.d. injection, skin GVHD developed
in all mice manifested on day 7 with widespread vacuolar
changes, apoptosis of keratinocytes, and lymphocytic infiltration
of the dermis and epidermis (Figure 2b–f). In contrast, i.d.
injection of the same number of OT-I cells into the ears of
control C57BL/6 (syngeneic) (Figure 2a) and BALB/c (allogeneic)
(data not shown) mice did not cause skin GVHD. Injection of
purified control CD8þ C57BL/6 T cells into the ears of K14-
mOVA(6) Tg and C57BL/6 mice also did not cause local
reactions (data not shown). Thus, localized GVHD reactions
were specific for OT-I cells encountering OVA Ag within the
skin of all K14-OVA Tg mouse lines, independent of the level of
OVA mRNA expression, or susceptibility of lines to develop
systemic GVHD after i.v. transfer of OT-I cells.
I.d. injection of OT-I cells causes activation of LCs within the
skin on day 2 and GVHD-like changes by day 3
Histologically, GVHD reactions in skin after i.d. injection were
much more severe than previously observed in the systemic
GVHD model (Shibaki et al., 2004). To understand the
mechanism of this local reaction, epidermal sheets were
stained with antibodies against MHC II molecules on day 2
after i.d. injection of 2 106 OT-I cells in 20ml of phosphate-
buffered saline (PBS). Clusters of enlarged LCs with elongated
dendrites were evident, suggesting maturation in the epidermis
(Figure 3b). Maturation of LCs was also evident after injection
of 20ml of PBS alone, suggesting that the i.d. injection itself
was sufficient to elicit maturation of LCs (Figure 3c).
A time-course experiment revealed that i.d. injection of
2106 OT-I cells consistently resulted in vacuolar changes on
day 3 with occasional apoptosis of keratinocytes (Figure 3d–g).
By day 4, a complete GVHD reaction could be consistently
identified (Figure 3g). Thus, the onset of GVHD occurred soon
after the activation of LCs within the epidermis. The sequence
and kinetics of events suggest that the maturation of LCs could
provide the requisite costimulatory signals that induce early
priming of OT-I cells that elicit rapid and severe local GVHD.
I.d. injection of OT-I cells induces expression of MHC II
molecules by keratinocytes
As previously described for acute GVHD reactions in skin,
we examined whether MHC II molecules were expressed on
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Figure 1. K14-OVA Tg mice express different levels of OVA mRNA.
Ovalbumin (OVA) mRNA expression was quantified by real-time RT–PCR
using total RNA extracted from the ears of all strains of K14-OVA Tg mice
(-mOVA(3), -sOVA(5), -mOVA(6), -sOVA(15), and -sOVA(17)) and control
C57BL/6 mice. All measurements were performed in triplicates and
normalized to endogenous levels of b-actin. Standard error bars are included.
The notations m and s indicate whether the epidermal OVA is targeted to the
keratinocyte membrane (m) or is in soluble (s) form.
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keratinocytes after i.d. injection of OT-I cells (Breathnach and
Katz, 1983; Breathnach et al., 1986). After injection of OT-I
cells, epidermal sheets stained for MHC II on day 4 showed
widespread keratinocyte MHC II expression (Figure 3i). This
was not yet obvious on day 2 (Figure 3b). It has been
previously reported that systemic administration of IFN-g to
normal mice caused similar MHC II expression by keratino-
cytes (Gaspari and Katz, 1988). Whether the response of
keratinocytes in the localized GVHD reaction is because of
IFN-g secretion by effector OT-I cells is uncertain. However,
i.d. injection of 100,000U of murine IFN-g (mIFN-g) into
C57BL/6 mice daily for 2 days showed similar keratinocyte
MHC II expression on day 3 (Figure 3k). These results indicate
that the development of GVHD reactions in skin coincided
with keratinocyte MHC II expression, as reported in other
mouse models of GVHD (Breathnach and Katz, 1983;
Breathnach et al., 1986).
OT-I cells proliferate and become activated within the dermis
of the K14-mOVA(6) Tg mouse ears
On maturation, LCs emigrate from the epidermis with the
help of inflammatory cytokines such as tumor necrosis factor-a
and IL-1b (Cumberbatch et al., 1997; Stoitzner et al., 1999).
Given the activation of LCs on day 2, OT-I cells were
extracted directly from the dermis of the K14-mOVA(6) Tg
mouse ears on day 2 after i.d. injection. CFSE-labeled OT-I
cells proliferated (Figure 4a–d) and the OT-I cells exhibited
upregulation of the CD69 activation marker (Figure 4e).
Interestingly, the draining LN of the injected K14-mOVA(6)
Tg mouse ear did not contain significant numbers of CFSEþ
OT-I cells on day 2 in contrast to the draining LN of the
control C57BL/6 mouse ear (Figure 4c and d). Thus, it appears
that OT-I cells are activated locally, presumably by resident
skin APCs, rather than in draining LNs. To additionally test
this hypothesis, we used GFPþ OT-I cells. An i.d. injection of
2106 GFPþ OT-I cells into the K14-mOVA(6) mouse ears
showed that few GFPþ OT-I cells traveled to the draining
LN in the first 72 hours, whereas most appear on day 14
(Figure 4f). In contrast, GFPþ OT-I cells readily appeared in
control C57BL/6 mice in the draining LN at 6, 24, and
72 hours, and disappeared by day 14 in the absence of Ag
stimulation. These results show that the GFPþ OT-I cells do
not migrate to the draining LN in significant numbers in the
K14-mOVA(6) Tg mice during the expected time period
(B48 hours) required for T-cell priming in the LN (Mempel
et al., 2004). This is likely because of the proliferation of OT-I
cells as they directly encounter an activating signal within the
skin, and not in the draining LN, and thereby acquire effector
function(s).
Conditional ablation of epidermal LCs does not abrogate local
GVHD in K14-mOVA(6) Tg mice
To begin the assessment of contributions of resident skin APCs,
K14-mOVA(6) Tg mice were crossed with Langerin-DTR Tg
mice that express DTR under control of a Langerin promoter
(12). K14-mOVA(6) Langerin-DTR double Tg mice were
injected i.p. with 500ng of DT to ablate LCs in the epidermis
after 48hours (Figure 5a and b), as previously reported (Bennett
et al., 2005). OT-I cells were then i.d. injected 4 days after LC
ablation, and the treated ears were harvested for hematoxylin
and eosin staining, whereas untreated ears were stained with
anti-MHC II antibody to verify complete ablation of LCs 5 days
after OT-I injection (Figure 5c and e). On day 5 after i.d.
injection of OT-I cells, LC-ablated K14-mOVA Langerin-DTR
Tg mice developed local GVHD similar to DT-treated normal
K14-mOVA(6) Tg controls (Figure 5g and h). These results
indicate that conditional ablation of LCs does not abrogate
local GVHD reactions.
Impairment of dDCs and ablation of epidermal LCs does not
abrogate local GVHD in K14-mOVA(6) Tg mice
Langerhans cell populations in the epidermis are radio-
resistant, in contrast to other DC subsets in mice
(Merad et al., 2002). Therefore, irradiation followed by
Figure 2. GVHD-like skin lesions developed following i.d. injection of OT-I cells. Hematoxylin and eosin histology (400) of the ears from (a) control
C57BL/6, (b) K14-mOVA(3), (c) K14-sOVA(5), (d) K14-mOVA(6), (e) K14-sOVA(15), and (f) K14-sOVA(17) Tg mice after i.d. injection of 2106 OT-I cells.
Skin biopsies from all K14-OVA Tg mouse strains exhibited basal vacuolar changes, apoptotic keratinocytes, and lymphocytic infiltration characteristic of
GVHD on day 7 after treatment. Scale bar is 100 mm.
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transfer of CD45 congenic b2m) bone marrow cells results in
hematopoietic chimeras with recipient-derived LCs and
donor-derived DCs in the LNs, spleen, and dermis. As b2m
cells do not express MHC I molecules and therefore cannot
present OVA peptide to OT-I cells, Ag presentation by dermal
and lymphoid APCs are impaired (Koller et al., 1990). To
determine the contribution of dDCs to the local GVHD
reaction, hematopoietic chimeras of the K14-mOVA(6) Tg
mice were established. After reconstitution with b2m bone
marrow cells, mice were assessed for chimerization by FACS
analysis of epidermal, dermal, LN, and spleen suspensions.
The vast majority of the LCs from epidermal cell suspensions
were recipient-derived (CD45.2) (Figure 6a), whereas 490%
of MHC IIhigh cells from dermal cell suspensions (Figure 6b)
and 498% of MHC IIhigh cells in the LNs and spleen were
donor-derived (CD45.1) (Figure 6c and d). Though not
entirely depleted (approximately 10% of the dermal
MHC IIhigh cells remained recipient-derived as previously
reported), the vast majority were replaced by donor-derived
b2m cells (Bogunovic et al., 2006). I.d. injection of OT-I cells
into K14-mOVA(6) Tg mice, whose OVA-presenting capacity
was limited to LCs (b2m-K14-mOVA(6)), resulted in a local
GVHD reaction (Figure 7d) similar to that seen in
K14-mOVA(6) Tg mice chimerized with wild-type littermate
(B6.SJL) bone marrow cells (BJ.SJL-K14-mOVA(6)) (Figure
7c). Therefore, b2m chimeras of K14-mOVA(6) Langerin-
DTR Tg mice were generated to eliminate Ag presentation by
all skin DCs. Surprisingly, the K14-mOVA(6) Langerin-DTR
Tg mice that had been chimerized with b2m bone marrow
and then treated with DT (LC-depleted) also developed local
GVHD after OT-I injection (Figure 7b). These results indicate
that skin DCs (LCs and dDCs) are not critical for the induction
of local GVHD in K14-mOVA(6) Tg mice.
Depletion of LCs from K14-mOVA(6) Langerin-DTR Tg
epidermal cells abrogates the induction of an MELR in the
presence of OT-I cell stimulation
Given the unexpected result that the functional elimination of
all skin DCs did not abrogate the GVHD reaction in vivo, the
activation of OT-I cells was further investigated in vitro. K14-
mOVA(6) Langerin-DTR Tg mice and littermate K14-
mOVA(6) Tg mice were treated with 500 ng of DT i.p. After
48 hours, epidermal cell suspensions were prepared and LC
depletion was verified. DT treatment resulted in 450-fold
reduction in the percentage of MHC IIþ LCs recovered from
the epidermal cell suspensions after enrichment by gradient
centrifugation (Figure 8j and k).
When either K14-mOVA(6) Tg or K14-mOVA(6)
Langerin-DTR Tg epidermal cell suspensions, not enriched
for LCs, were cultured with CFSE-labeled OT-I cells, the OT-I
cells proliferated (Figure 8b and c). However, proliferation
was not observed when OT-I cells were cultured with either
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Figure 3. An i.d. injection of OT-I cells caused activation of LCs and GVHD-
like histological changes. Epidermal sheets were separated from mouse ears
and stained for MHC II molecules to visualize LCs ( 200) on day 2.
Representative data from C57BL/6 and K14-mOVA(6) Tg mouse ears:
(a) untreated controls, (b) following injection of 2 106 OT-I cells in 20ml PBS,
and (c) after injection of 20 ml PBS. Both mice injected with OT-I cells and
those injected with PBS alone showed enlarged LCs with elongated dendrites,
suggestive of maturation. Hematoxylin and eosin histology (200) of the ears
from K14-mOVA(6) Tg mice after injection of 2 106 OT-I cells on (d) day 1,
(e) day 2, (f) day 3, and (g) day 4. Characteristic basal vacuolar changes,
apoptotic keratinocytes, and lymphocytic infiltration were clearly evident by
day 3. Epidermal sheets were separated from mouse ears and stained for MHC
II molecules (400 ) on day 4 after i.d. injection of 2106 OT-I cells into (h)
C57BL/6 mice and (i) K14-mOVA(6) Tg mice. The K14-mOVA(6) Tg mice
exhibited widespread MHC II molecule expression on keratinocytes in a
manner not observed in control C57BL/6 mice. Epidermal sheets were
separated from mouse ears and stained for MHC II (400) on day 3 in C57BL/6
mice i.d. injected with (j) 20 ml of PBS or (k) 100,000U of mIFN-g in 20 ml of
PBS for 2 dyas. The mIFN-g-injected mice (k) exhibited widespread
keratinocyte MHC II expression in a manner similar to K14-mOVA(6) mice
after i.d. injection of OT-I cells (i) but not observed in control C57BL/6 mice
(H). Scale bar is 100 mm.
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control C57BL/6 or K14-mOVA(6) b2m Tg epidermal cells
(Figure 8a and d). The latter control was used to rule out the
possibility that contaminating DCs in the OT-I cell suspen-
sion could be responsible for cross-presentation of OVA Ag
directly to the OT-I cells. Furthermore, both K14-mOVA(6) Tg
and K14-mOVA(6) Langerin-DTR Tg epidermal cells
(Figure 8f and g) induced IFN-g production by the OT-I cells
and upregulation of CD25, CD44, and CD69 activation markers
in contrast to that induced by control C57BL/6 and K14-
mOVA(6)b2m Tg epidermal cells (Figure 8e, h–i). How-
ever, these same LC-depleted K14-mOVA(6) Langerin-DTR
Tg epidermal cells that induced OT-I proliferation (Figure 9a)
did not induce an MELR when cultured with allogeneic
BALB/c T cells (Figure 9b). These results indicate that OVA-
expressing keratinocyte suspensions, in the absence of skin
DCs, can directly prime OT-I cells.
We used two other methods to verify that skin DCs were
dispensable for Ag presentation. The first method involved
harvesting keratinocytes from neonatal K14-mOVA(6) Tg
mouse epidermis and eliminating the vast majority of LCs by
repeated depletion using an AutoMACS separator (Miltenyi
Biotech, Boston, MA) after incubating with MHC II microbe-
ads. Using this method, the percentage of LCs in the
epidermal cell suspensions was reduced to approximately
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Figure 4. Autoreactive T-cell proliferate, are activated, and remain in the dermis of K14-mOVA(6) Tg mice on day 2 after i.d. injection. Naive OT-I cells
were labeled with CFSE dye and i.d. injected at a dose of 2 106 cells into the ears of K14-mOVA(6) Tg mice and control C57BL/6 mice. The dermal
OT-I cells were extracted on day 2 for FACS analysis and proliferated in the (a) K14-mOVA(6) Tg mice but not in the (b) control C57BL/6 mice . The draining
LNs were also harvested on day 2 for FACS analysis and the CFSEþ non-proliferating OT-I cells were readily detectable in the LN of (d) control C57BL/6
mice but few cells were present in LNs of (c) K14-mOVA(6) Tg mice. Cells were gated on CFSEþ /CD8þ cells. GFPþ OT-I cells were also i.d. injected at
a dose of 2106 cells into K14-mOVA(6) Tg mice and control C57BL/6 mice, and the dermal OT-I cells were extracted on day 2 for FACS analysis.
(e) The GFPþ OT-I cells in the K14-mOVA(6) Tg mice expressed enhanced amounts of CD69 on day 2 compared with those injected into C57BL/6 mice.
(f) GFPþ OT-I cells were i.d. injected at a dose of 2106 cells into K14-mOVA(6) Tg and control C57BL/6 mice and draining LN OT-I cells were harvested
at 6, 24, and 72 hours, and on day 14. Few GFPþ OT-I cells were detected in the LNs of K14-mOVA(6) Tg mice in contrast to control C57BL/6 mice at 6, 24,
and 72 hours. On day 14, GFPþ OT-I cells were readily detected in the LNs of K14-mOVA(6) Tg mice but not in control C57BL/6 mice.
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0.001% following three rounds of depletion through the
AutoMACS separator (Figure 10a). Despite this marked
depletion of MHC IIþ cells from the neonatal K14-mOVA(6)
Tg epidermal cell suspensions, OT-I cell proliferation ensued
when incubated with these cells (Figure 10b). As shown with
the K14-mOVA(6) Langerin-DTR depleted of LCs using DT,
the LC-depleted neonatal K14-mOVA(6) Tg epidermal cells
also did not elicit an MELR when cultured with allogeneic
BALB/c T cells after depletion through the AutoMACS
separator (Figure 10c).
The second method involved culturing primary neonatal
keratinocytes from K14-mOVA(6) mice in low calcium
medium and selectively removing the supernatant to reduce
the number of LCs in the suspension. This method allows for
the proliferating keratinocytes to remain adherent to the Petri
dish for retrieval, whereas the LCs in suspension are
eliminated. By this method, the percentage of LCs in the
epidermal cell suspensions was reduced to approximately
0.26% after 3 days of culture (data not shown). Whether the
initial keratinocyte suspension placed into culture was non-
depleted (crude) or depleted of LCs using the AutoMACS
separator, the reduction in the number of LCs was sufficient
to abrogate an MELR when cultured with allogeneic
BALB/c T cells in the presence of OT-I cell stimulation
Figure 5. Local GVHD developed in DT-treated K14-mOVA(6) Langerin-DTR double Tg mice after i.d. injection of OT-I cells. Langerhans cell (LC) ablation
was confirmed at 48 hours after DT treatment in (b) K14-mOVA(6) Langerin-DTR Tg mice but not in (a) control C57BL/6 mice by staining epidermal sheets for
MHC II molecules. On day 4 after DT treatment, K14-mOVA(6) Langerin-DTR Tg mice were i.d. injected with 2 106 OT-I cells and treated ears were
harvested on day 5 after OT-I treatment. Untreated ears were harvested on the same day (day 9 after DT treatment) and LC ablation was confirmed in (d)
K14-mOVA(6) Langerin-DTR Tg mice but not in control (c) C57BL/6 and (e) K14-mOVA(6) Tg mice. Hematoxylin and eosin histology ( 400) showed local
GVHD-like changes in DT-treated (g) K14-mOVA(6) Langerin-DTR Tg mice on day 5 after i.d. injection of OT-I cells as in DT-treated normal (h) K14-mOVA(6)
Tg mice but not in DT-treated (f) control C57BL/6 mice. Scale bar is 100 mm.
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chimeras remained recipient-derived (CD45.2þ ) 8 weeks after
transplantation. MHC IIhigh cells in the (b) dermis, (c) CLN, and (d) spleen
were mostly donor-derived (CD45.1þ ) 8 weeks after transplantation.
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(data not shown). Furthermore, these keratinocyte suspen-
sions induced an activated cell-surface phenotype on the OT-
I cells with upregulation of CD25, CD44, and CD69, and
downregulation of CD62L (data not shown). These additional
results, using different methods, further support the conclu-
sion that keratinocytes can directly present OVA peptide and
induce an OT-I cell response.
DISCUSSION
In this localized GVHD model, OT-I cells elicit skin GVHD
reactions after i.d. injection of OVA-reactive CD8 cells (OT-I)
into Tg mice that express OVA in epidermal keratinocytes.
We used this model to investigate the in vivo and in vitro
contribution of skin DCs (LCs and dDCs) to present epidermal
Ag by conditional ablation of epidermal LCs and impairment
of MHC I presentation on dDCs. Unexpectedly, the elimina-
tion of LCs and the impairment of dDCs did not abrogate
localized GVHD reactions. In addition, using two different
methods of cell preparation, a 499% reduction in the
number of LCs in vitro completely abrogated the induction of
MELRs without attenuating the priming of OT-I cells by the
same OVA-expressing epidermal cells. These results strongly
suggest that keratinocytes expressing endogenous tissue Ags
(OVA) can directly prime naive T cells (OT-I cells).
Langerhans cells have traditionally been considered the
primary APCs involved in the initiation of T-cell responses in
the skin (Silberberg-Sinakin et al., 1976; Silberberg-Sinakin
and Thorbecke, 1980; Macatonia et al., 1987). Previous
studies have implicated LCs as critical mediators of allo-
geneic GVHD and CD8þ T–cell responses to epidermal self-
Ag (Mayerova et al., 2004; Merad et al., 2004). More
complex models using murine Herpes simplex virus and
Leishmania have suggested that LCs do not have a significant
role in Ag presentation (Allan et al., 2003; Zhao et al., 2003;
Ritter et al., 2004). More recently, classical CHS experiments
using LC-deficient mice have shown that LCs are dispensable
for the elicitation of CHS responses (Bennett et al., 2005;
Kaplan et al., 2005; Kissenpfennig et al., 2005). Collectively,
these studies have supported the notion that dDCs are the
critical mediators of T-cell responses in the skin. It has also
been reported that under inflammatory conditions, such as
CHS reactions, Gr1þ circulating DCs may be responsible for
the cross-priming of CD8þ T cells in a CCR6-dependent
manner in the epidermis (Le Borgne et al., 2006). As such, the
precise contribution of DCs (or other cells) to immune
responses in the skin remains unclear. A recent study showed
that natural killer cells mediate CHS responses independent
of T and B cells in the skin (O’Leary et al., 2006). It has also
been reported that other cell populations in the epidermis,
such as keratinocytes under the influence of IFN-g, can
directly stimulate T cells with a variety of stimuli including
Herpes simplex virus Ags and superantigens (Cunningham
and Noble, 1989; Nickoloff et al., 1993). However, these
studies involved a mixed population of responder CD4þ and
CD8þ T cells and the authors postulated that the immune
response was initiated by the priming of CD4þ T cells. It is
more commonly believed that, owing to the absence of
costimulatory molecules, the presentation of Ag by keratino-
cytes, particularly in the steady state, induces CD4þ T-cell
anergy rather than priming (Gaspari et al., 1988; Bal et al.,
1990). In this study, we sought to investigate these questions
using an in vivo model with a defined self-Ag (OVA)
expressed in the epidermis and using a specified monoclonal
population of CD8þ T cells (OT-I cells).
To examine the role of LCs in the cross-presentation of
epidermal OVA, we crossed the K14-mOVA(6) Tg mice onto
a Langerin-DTR Tg background (Bennett et al., 2005).
Interestingly, after the ablation of LCs with DT, the K14-
mOVA(6) Langerin-DTR Tg mice still developed local
GVHD with i.d. injection of OT-I cells. These results are
consistent with the lack of abrogation of CHS observed in
previous studies using DT-based technology to ablate LCs
Figure 7. GVHD developed in b2m-K14-mOVA(6) Tg and b2m-K14-mOVA(6) Langerin-DTR Tg bone marrow chimeras after both i.d. injection
of OT-I cells and treatment with DT. Hematoxylin and eosin histology ( 200) of the ears from (a) B6.SJL-K14-mOVA(6) Langerin-DTR Tg,
(b) b2m-K14-mOVA(6)  Langerin-DTR Tg, (c) B6.SJL-K14-mOVA(6) Tg, (d) b2m-K14-mOVA(6) Tg, and (e) b2m-C57BL/6 X-irradiated, bone
marrow-reconstituted chimeras after i.d. injection of 2 106 OT-I cells. Skin biopsies from all chimeras (a–d) except control b2m-C57BL/6 chimeras
(e) showed GVHD-like skin lesions. Scale bar is 100mm.
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(Bennett et al., 2005; Kaplan et al., 2005; Kissenpfennig et al.,
2005). However, these studies did not examine the effects of
impairing dDCs on CHS.
To identify the role of dDCs in the cross-presentation of
epidermal OVA, we generated bone marrow chimeras that
have MHC I-deficient (b2m) dDCs in the K14-mOVA(6) mice.
This was done because of the striking systemic GVHD
phenotype that we previously reported in this particular strain
(Shibaki et al., 2004). Lethally irradiated mice reconstituted
with donor b2m bone marrow retain recipient LCs while
allowing for the impairment of MHC I-dependent Ag
presentation by dDCs (Merad et al., 2002). Despite the
impairment of cross-presentation by MHC I molecules in the
dermis, LN, and the spleen, these mice developed local
GVHD after i.d. injection of OT-I cells. Surprisingly, even
when K14-mOVA(6) Langerin-DTR Tg mice were chimer-
ized with b2m bone marrow and depleted of LCs with DT,
local GVHD ensued after OT-I injection. In contrast to our
results, Azukizawa et al. (2003) reported complete
abrogation of OT-I cell proliferation in vivo through similar
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reconstitution studies in their K5-mOVA Tg mice. This would
suggest that LCs are not the primary APCs involved in OT-I
cell responses in their model but that either dermal or other
lymphoid-resident DCs may subserve this role. However, in
our model, neither epidermal LCs nor dDCs appear to be
absolutely critical for the induction of local GVHD.
To better assess the mechanism by which GVHD occurred
in vivo despite the functional elimination of skin DCs,
epidermal cells from LC-depleted K14-mOVA(6) Langerin-
DTR Tg mice were cultured with OT-I cells in vitro.
Interestingly, despite the drastic reduction of LCs (450-fold)
in the epidermal cells, OT-I cells were still stimulated
(proliferated, activated, and acquired effector function) to a
similar degree as when mixed with littermate control K14-
mOVA(6) Tg epidermal cells. Furthermore the LC-depleted
epidermal cells could not induce a MELR, suggesting that the
reduction in LCs was sufficient to abrogate other modes of
physiologically relevant APC-dependent responses. These
striking in vitro results corroborate the in vivo findings that
despite the impairment or elimination of almost all skin DCs,
GVHD ensues because of the underlying accessory cell
function of keratinocytes. These results are further reinforced
by a recent study showing that LCs in the skin are not
required for skin graft rejection in mice mismatched for MHC
Ags. In fact, it appears that the lack of LCs may even enhance
graft rejection in mice mismatched for minor histocomp-
ability Ags (Obhrai et al., 2008).
Accessory cell function of keratinocytes has recently been
addressed specifically with regard to MHC I-specific pre-
sentation to a population of CD8þ T cells. In contrast to the
findings reported in our study, Stoitzner et al. (2006) showed
that LCs rather than keratinocytes present endogenous
epidermal OVA to OT-I cells using a similar K14-OVA Tg
mouse model. Indeed, we also found that purified LCs can
induce CD8 T-cell (OT-I) proliferation. In their study,
Stoitzner et al. (2006) used 3-day cultured cells that were
sorted according to the presence or absence of MHC class II
positivity. The MHC class II cells (keratinocytes) from their
K14-OVA peptide Tg mice did not induce T-cell proliferation.
However, as the data for these experiments were ‘‘not
shown,’’ no comparison can be made between their
experimental procedures as well as data and this study.
Furthermore, the data to which they refer relate only to the
K14-OVA SIINFEKL peptide mice that differ from our Tg mice
that are Tg for a large segment of the OVA protein (9). In our
study, we report that keratinocytes directly present self-Ag to
CD8þ T cells to induce priming. This was shown using two
markedly different systems –DT-mediated depletion of DTR-
expressing LCs and depletion of LCs from neonatal keratino-
cyte suspensions using MHC II microbeads. Whether this
process is dependent on costimulatory molecules or is simply
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104
103
102
101
100
104103102101100 104103102101100
104103102101100104103102101100
K14-mOVA(6) ECs
C57BL/6 ECs
Proliferation of OT-I cells
K14-mOVA(6)
ECs
C57BL/(6)
ECs FL
4-
H
FL
4-
H
FL
4-
H
FL
4-
H
Class II
0
00
0000
00
98.9
99 100
1001.1
1.02
4.38e-3
Proliferation of BALB/c T cells
3 H
 T
hy
m
id
in
e 
in
co
rp
or
at
io
n
(c.
p.m
.) 100,000
150,000
50,000
0
5,000
10,000
15,000
20,000
0
Before separation After separation
Before
separation
After
separation
Before
separation
After
separation
Figure 10. Depletion of Langerhans cells using MHC II microbeads from
neonatal K14-mOVA(6) epidermal cells simultaneously abrogated allogeneic
mixed epidermal lymphocyte reactions while inducing OT-I cell
proliferation. (a) Depletion of LCs using MHC II microbeads resulted in a
reduction of the percentage of LCs in the neonatal K14-mOVA(6) Tg
epidermal cell suspensions from 2.45 to 0.001% of the total population.
(b) Neonatal K14-mOVA(6) Tg epidermal cell suspensions after LC-depletion
through the AutoMACS separator resulted in the same level of OT-I cell
proliferation as in non-depleted control epidermal cell suspensions. Negative
control neonatal C57BL/6 epidermal cell suspensions did not induce OT-I cell
proliferation. (c) Both neonatal K14-mOVA(6) and C57BL/6 epidermal cells
did not induce allogeneic BALB/c T-cell proliferation after depletion of LCs
using MHC II microbeads.
50,000
40,000
30,000
20,000
10,000
0
C57BL/6
T cells
BALB/c
T cells
C57BL/6 EC
K14-mOVA(6) EC
K14-mOVA(6) ECK14-mOVA(6) ×
Langerin-DTR EC K14-mOVA(6) ×Langerin-DTR EC
0
5,000
10,000
15,000
3 H
 T
hy
m
id
in
e 
in
co
rp
or
at
io
n 
(c.
p.m
.)
Figure 9. Diphtheria toxin-mediated depletion of Langerhans cells from
K14-mOVA(6) Langerin-DTR Tg epidermal cells simultaneously abrogated
allogeneic mixed epidermal lymphocyte reactions while inducing OT-I cell
proliferation. (a) Day 3 of [3H]thymidine proliferation assay of OT-I cells
cultured with crude epidermal cells from DT-treated C57BL/6, littermate
K14-mOVA(6), and K14-mOVA(6) Langerin-DTR Tg mice. (b) Day 5 of
[3H]thymidine proliferation assay of allogeneic BALB/c and syngeneic
C57BL/6 T cells cultured with crude epidermal cells from DT-treated
littermate K14-mOVA(6) and K14-mOVA(6) Langerin-DTR Tg mice. All
measurements were performed in triplicates. SE bars are included.
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because of the high density of self-peptide on MHC I
complexes remains to be elucidated. Furthermore, these
findings do not preclude the role of LCs or dDCs in these
reactions under normal physiological conditions.
Keratinocytes have been reported to directly activate
autoreactive CD4 T cells in the context of tissue inflammation
(Fan et al., 2003). In this study, Fan et al. (2003) propose
that an inflammatory stimulus mobilizes IL-1 and/or
tumor necrosis factor-a to induce the upregulation of
MHC molecules on the surface of keratinocytes to allow
them to act as primary APCs. It is possible that the
inflammation associated with i.d. injection creates a
similar context in which keratinocytes can act as APCs to
present OVA Ag directly to OT-I cells. Nonetheless, our
studies show, for the first time, that naive autoreactive CD8 T
cells can be directly primed by keratinocytes in an Ag-
specific manner.
There remains the possibility that very small numbers of
dermal DCs are sufficient to induce the priming of OT-I cells
even in the absence of detectable allostimulation. However,
given the fact that T cells respond in a dose-dependent
manner to the number of stimulator DCs, if such were the
case, we would still expect a drastic reduction in the OT-I
cell response after depletion of LCs and this is not observed.
We previously reported that approximately 1,000 migratory
LCs from skin explants of K14-mOVA(6) Tg mouse ears were
required to induce a minimal detectable level of OT-I cell
proliferation in vitro and only at 10,000 stimulator LCs was a
significant level of proliferation observed (Shibaki et al.,
2004). A generous approximation would suggest that the LC-
depleted epidermal cell suspensions contain B100 remain-
ing stimulator LCs after DT treatment, in contrast to B5,000
stimulator LCs in the undepleted epidermal cell suspensions.
For the neonatal epidermal cell suspension, the number of
remaining stimulator LCs would be even lower on the order
of B1–2 cells after depletion with MHC II microbeads and
the AutoMACS separator. Thus, it seems highly unlikely that
such small numbers of OVA-bearing LCs could induce such
robust priming of naive OT-I cells.
In summary, we have developed an efficient i.d. injection
model whereby a local GVHD reaction can be elicited in
multiple strains of K14-OVA Tg mice that express both
soluble and membrane-bound forms of OVA at different
levels of expression. This model provides a novel approach to
study the mechanisms underlying the presentation of
epidermally expressed self-Ag by specific populations of
skin-resident cells. We have shown both in vivo and in vitro,
by the elimination of skin DCs, that keratinocytes can
function as accessory cells even in the absence of functional
APCs. In addition to gaining mechanistic insights, we believe
that this is an effective method by which to test potential
therapies, both topical and systemic, that modulate cell-
mediated skin diseases.
MATERIALS AND METHODS
Mice
All K14-OVA Tg mouse lines were obtained from the National
Cancer Institute Animal Production Program (Frederick, MD),
housed in a clean (not pathogen-free) facility that does not allow
MHV or pinworms, and were bred and used with institutional
approval. OT-IRAG-1-deficient mice were purchased from
Taconic (Germantown, NY) and UBI-GFP/BL6 mice were purchased
from The Jackson Laboratory (Bar Harbor, ME).
Generation of Tg mice
The generation of the K14-mOVA(6) Tg mouse expressing mem-
brane-associated OVA under a K14 promoter was previously
described (Shibaki et al., 2004). The K14-mOVA(3) Tg mouse was
generated in the same manner. The Tg mice (K14-sOVA(5), K14-
sOVA(15), and K14-sOVA(17 Tg)) expressing soluble OVA (sOVA)
were prepared by excising the OVA fragment (100–1167) from the
TC-OVA plasmid (Lim et al., 1998) with BgIII and BamHI. The vector
sequence encoding b-galactosidase was excised from a K14-bgal
plasmid (Shibaki et al., 2004) with NotI and subsequently replaced
with the OVA fragment by blunt-end ligation with T4 polymerase to
make the pK14-sOVA plasmid. The sOVA plasmids do not contain
the PDGFR, HA, or Myc sequences. All subsequent steps were the
same as for the generation of the K14-mOVA Tg mouse lines.
Quantitative real-time RT–PCR
Total RNA was extracted from all strains of K14-OVA Tg mice using
the RNeasy Mini Kit (QIAGEN, Valencia, CA) and reverse
transcribed with the StrataScript First-Strand Synthesis System
(Stratagene, Cedar Creek, TX). The resulting cDNAs were used for
real-time PCR using the SYBR-Green PCR Master Mix (Applied
Biosystems, Foster City, CA) in triplicates (OVA-1, 50-GGCAT
CAATGGCTTCTGAGAA-30; OVA-2, 50-CCAACATGCTCATTGTCC
CA-30). All quantitations were normalized to endogenous control
b-actin (b-actin-1, 50-TGACAGGATGCAGAAGGAGA-30; b-actin-2,
50-GTACTTGCGCTCAGGAGGAG-30). PCR and data collection
were performed on the ABIS PRISM 7700 Sequence Detector (Perkin
Elmer, Rockville, MD).
I.d. injection of OT-I cells
Single-cell suspensions were prepared from LNs of OT-IRAG-1-
deficient or F1 (GFPþ OT-I) mice, further purified for CD8þ cells
using CD8 columns (R&D Systems, Minneapolis, MN), and
resuspended in RPMI with 5% fetal calf serum. Before injection,
2 106 OT-I cells were resuspended in 20 ml of PBS and injected
intradermally into the left ears of K14-OVA Tg, K14-OVA Langerin-
DTR Tg, control C57BL/6, or x-irradiated bone marrow-reconstituted
chimeric mice. The mice were anesthetized by i.p. injection of 50mg
xylazine (Phoenix Pharmaceuticals, Burlingame, CA) and 2.5mg of
ketamine (Fort Dodge, Madison, NJ) in 250ml of PBS just before the
i.d. injection.
Preparation of epidermal sheets and fluorescent microscopy
Epidermal sheets were prepared as previously described (Caughman
et al., 1986) and stained with mouse-anti-I-Ab followed by secondary
fluorescein-conjugated IgG Fab02 fragments of goat-anti-mouse IgG
(Biosource, Bethesda, MD). Images were captured using a Nikon
Eclipse TE300 camera and IPLab software (Tokyo, Japan). An i.d.
injection of mIFN-g (Peprotech, Rocky Hill, NJ) was performed at a
dose of 100,000U in 20 ml of PBS once a day for 2 days and
epidermal sheets were prepared on day 3.
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Histological analyses
Ear samples were prepared from K14-OVA Tg mice at various times
after i.d. injection of OT-I cells and fixed in 10% neutral-buffered
formalin. Paraffin-embedded tissues were sectioned and stained with
hematoxylin and eosin using standard techniques (American
Histolabs, Rockville, MD).
Flow cytometry
For monitoring T-cell proliferation, 2 106 CFSE-labeled OT-I cells
were i.d. injected into the left ears of recipient K14-OVA Tg mice. On
day 2 after i.d. injection, CFSE-labeled OT-I cells were harvested from
the left cervical LNs and from the dermis (see below) and stained with
APC-conjugated anti-CD8 mAbs for FACS analysis. For monitoring of
T-cell migration, 2 106 OT-I cells isolated from F1 (GFPþ OT-I)
mice were i.d. injected into the left ears of recipient K14-OVA Tg
mice. At 6, 12, 24, 48, 72hours, and 14 days, the left cervical LNs
were harvested and stained with biotin-conjugated anti-Vb5 mAbs.
APC-conjugated streptavidin was used for visualization of the biotin-
conjugated mAb. For staining of activation markers, phycoerythrin-
conjugated and APC-conjugated anti-CD25, -CD44, -CD62L, -CD69,
and isotype control antibodies were used. Experiments were performed
on an FACSCalibur (San Jose, CA) and analyzed using CellQuest
software (Becton Dickinson, Franklin Lakes, NJ).
Dermal extraction of OT-I cells
Autoreactive T cells were extracted from the dermis by mechanically
splitting the dorsal and ventral halves of mouse ears on day 2 after i.d.
injection. The split ears were then floated on a solution of 0.50mg/ml
Liberase CI (Roche Applied Science, Branford, CT) in RPMI for 1hour
at 37 1C and the dermis was mechanically scraped into the Liberase CI
suspension. The suspension was diluted in RPMI with 5% fetal calf
serum and 0.05% DNase and then filtered through a 70mm filter. The
recovered cells were then washed once in PBS with 5% fetal calf
serum and stained with antibodies for FACS analysis.
Generation of x-irradiated bone marrow-reconstituted
chimeras
Seven- to eight-week-old recipient CD45.2þ C57BL/6, K14-
mOVA(6), or K14-mOVA(6) Langerin-DTR mice were lethally
irradiated (9Gy) and reconstituted by i.v. injection of 1 107 bone
marrow cells from CD45.1þ B6.SJL or b2m mice. Eights weeks after
transplantation, ears, cutaneous LNs (CLNs), and spleens were
harvested. Ears were split into dorsal and ventral halves and
incubated in 0.5% trypsin and EDTA (5mM) in PBS (Gibco, Carlsbad,
CA) for 60–90minutes at 37 1C to allow for separation of epidermal
and dermal sheets. Epidermal sheets were made into a single-cell
suspension and isolated by Lympholyte-M (Cedarlane, Burlington,
NC) gradient. Dermal sheets were further incubated in 0.5mg/ml
Collagenase IA (Sigma, St Louis, MO) and 0.05% DNase (Sigma) and
made into a single-cell suspension. LNs and spleens were made into
single-cell suspensions. All cells were stained with various combina-
tions of the following antibodies (BD Pharmingen, San Diego, CA):
FITC-conjugated anti-CD45.1, CD45.2, and isotype mouse IgG2a;
phycoerythrin-conjugated or APC-conjugated anti-I-A/I-E.
Depletion of LCs from K14-mOVA(6) Langerin-DTR Tg mice
Diphtheria toxin (BIOMOL, Plymouth Meeting, PA) was reconsti-
tuted with sterile distilled water at a concentration of 2.5 ng/ml and
injected at a dose of 500 ng i.p. Depletion of LCs was verified by
immunofluorescence staining of epidermal sheets as described
above.
Depletion of LCs from neonatal K14-mOVA(6) Tg mice
Primary keratinocytes were isolated from neonatal (days 1 to 3) K14-
mOVA(6) Tg and C57BL/6 whole mouse skin as previously described
(Steinman and Nussenzweig, 2002). The neonatal keratinocyte
suspensions were then incubated with anti-MHC II microbeads (clone
M5/114.15.2) at 4 1C for 15minutes and then run through an
AutoMACS separator (mode: DEPLETES) (Miltenyi Biotech). The
neonatal keratinocyte suspensions were reincubated with anti-MHC II
microbeads (clone M5/114.15.2) at 4 1C for 15minutes between runs
and serially depleted through two more rounds through the AutoMACS
separator. For verification and quantification of depletion of MHC IIþ
cells, the cell suspensions were stained with an FITC-conjugated anti-I-
A/I-E (clone 2G9) (BD Pharmingen) that binds a different epitope of
MHC II than the MHC II microbeads (clone M5/114.15.2).
Primary keratinocytes from neonatal (days 1 to 3) K14-mOVA(6)
Tg and C57BL/6 mice were cultured in Eagle’s minimal essential
medium supplemented with 0.05mM calcium chloride and 10%
Chelex (Sigma)-treated fetal bovine serum (Hyclone, Logan, UT) in
flat-bottom 96-well plates (1 105 cells per well) for 3 days as
previously published (Steinman and Nussenzweig, 2002). The
supernatants were removed and the adherent keratinocytes were
harvested by trypsinization and mixed with OT-I and BALB/c T cells
for proliferation assays. The OT-I and BALB/c T-cell suspensions
were also depleted of MHC IIþ cells using MHC II microbeads and
the AutoMACS separator and quantified by FACS analysis.
In vitro proliferation assays
Adult epidermal cells were prepared from littermate K14-mOVA(6)
Tg, K14-mOVA(6) Langerin-DTR Tg, K14-mOVA(6) b2m Tg, and
C57BL/6 mice as previously described (Sauder et al., 1982).
Neonatal epidermal cells were prepared from K14-mOVA(6) Tg
and C57BL/6 mice as previously described (Steinman and
Nussenzweig, 2002). Crude epidermal cells (1 105) were added
per well to a 96-well flat-bottom plate along with 5 104 CFSE-
labeled OT-I cells. On day 3, the cells were harvested and stained
with APC-conjugated anti-CD8 antibody and analyzed by FACS for
proliferation. The same conditions were used to stain for activation
markers of OT-I cells using the antibodies described above.
Alternatively, 1 105 crude epidermal cells were added per well to
a 96-well flat-bottom plate along with 5 104 unlabeled OT-I cells.
During the last 18hours of the culture period 1mCi of [3H]TdR was
added. On day 3, cells were harvested and cell-associated radio-
activity was counted by direct b-counting using a gas ionization
counter (Packard, Rockville, MD). For the MELRs, 4 105 crude
epidermal cells were added per well to a 96-well flat-bottom plate
along with 2 105 allogeneic BALB/c T cells or syngeneic C57BL/6 T
cells isolated by a mouse T-cell enrichment column (R&D Systems).
During the last 18hours of the culture period, 1mCi of [3H]TdR was
added. On day 5, cells were harvested and cell-associated radio-
activity was counted by direct b-counting using a gas ionization
counter (Packard). All cell cultures were performed in complete RPMI
media containing 1mg/ml indomethacin (Sigma) at 37 1C under 5%
CO2. To verify ablation, epidermal cell suspensions were enriched by
centrifugation over a Lympholyte-M (Cedarlane) gradient.
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Intracellular cytokine staining
Autoreactive T cells (1 106) were cultured along with
2 106 epidermal cells from K14-mOVA(6) Tg littermate,
K14-mOVA(6) Langerin-DTR Tg, K14-mOVA b2m Tg, and
C57BL/6 mice on 24-well flat-bottom plates in complete RPMI
containing 1 mg/ml indomethacin (Sigma) at 37 1C under 5% CO2.
After 3 days, cells were cultured on anti-CD3 antibody-coated (BD
Pharmingen) 24-well flat-bottom plates and GolgiPlug (BD Pharmin-
gen) was added at a concentration of 5 mg/ml. After 5 hours, cells
were harvested and stained with APC-conjugated anti-CD8 antibody
(BD Pharmingen) and fixed and permeabilized by incubation with
cytofix/cytoperm solution (BD Pharmingen). The permeabilized cells
were then stained with phycoerythrin-conjugated anti-IFN-g anti-
body (BD Pharmingen) and analyzed by FACS for IFN-g production.
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